Potential therapeutic applications of targeting signal-transducing adaptor protein-2 in autoimmune diseases

Abstract

Adaptor proteins are involved in various immune responses via the modulation of many signaling pathways. Signal-transducing adaptor protein-2 (STAP-2) is an adaptor protein that contains typical domains such as the pleckstrin homology (PH) domain, Src homology domain, and a proline-rich region from the N-terminal region. In T cells, STAP-2 positively regulates T cell receptor (TCR)-mediated signaling by associating with CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs) and lymphocyte-specific protein tyrosine kinase (LCK). Therefore, a peptide that inhibits the interaction between STAP-2 and CD3ζ ITAMs is likely to suppress TCR-mediated T cell activation, as well as T cell-mediated diseases. As expected, the peptide successfully inhibited the STAP-2/CD3ζ ITAM interaction and suppressed TCR-mediated signaling, cell proliferation, and interleukin (IL)-2 production in human/murine T cells. Furthermore, this inhibitor suppressed the pathogenesis of experimental autoimmune encephalomyelitis (EAE), which is widely recognized as a mouse model of multiple sclerosis, via the downregulation of T cell activation and infiltration of T helper (Th) 1/Th17 cells. These results suggest a new strategy for the treatment of multiple sclerosis and other immune diseases.

Keywords

Signal-transducing adaptor protein / adaptor protein / signal transduction / T cell receptor / immune response / autoimmunity / multiple sclerosis / peptides

References

[1] Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018; 18: 485-97.

[2] Flynn DC. Adaptor proteins. Oncogene. 2001; 20: 6270-2.

[3] Luo LY, Hahn WC. Oncogenic signaling adaptor proteins. J Genet Genomics. 2015; 42: 521-9.

[4] Jordan MS, Singer AL, Koretzky GA. Adaptors as central mediators of signal transduction in immune cells. Nat Immunol. 2003; 4: 110-6.

[5] Minoguchi M, Minoguchi S, Aki D, Joo A, Yamamoto T, Yumioka T, et al. STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif. J Biol Chem. 2003; 278: 11182-9.

[6] Matsuda T, Oritani K. STAP-2 adaptor protein regulates multiple steps of immune and inflammatory responses. Biol Pharm Bull. 2021; 44: 895-901.

[7] Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A, et al. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochem Biophys Res Commun. 2009; 384: 71-5.

[8] Ikeda O, Sekine Y, Mizushima A, Nakasuji M, Miyasaka Y, Yamamoto C, et al. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. J Biol Chem. 2010; 285: 38093-103.

[9] Sekine Y, Yamamoto T, Yumioka T, Sugiyama K, Tsuji S, Oritani K, et al. Physical and functional interactions between STAP-2/BKS and STAT5. J Biol Chem. 2005; 280: 8188-96.

[10] Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, et al. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci. 2011; 102: 756-61.

[11] Sekine Y, Yamamoto C, Kakisaka M, Muromoto R, Kon S, Ashitomi D, et al. Signal-transducing adaptor protein-2 modulates Fas-mediated T cell apoptosis by interacting with caspase-8. J Immunol. 2012; 188: 6194-204.

[12] Yamamoto T, Yumioka T, Sekine Y, Sato N, Minoguchi M, Yoshimura A, et al. Regulation of FcεRI-mediated signaling by an adaptor protein STAP-2/BSK in rat basophilic leukemia RBL-2H3 cells. Biochem Biophys Res Commun. 2003; 306: 767-73.

[13] Sekine Y, Nishida K, Yamasaki S, Muromoto R, Kon S, Kashiwakura J, et al. Signal-transducing adaptor protein-2 controls the IgE-mediated, mast cell-mediated anaphylactic responses. J Immunol. 2014; 192: 3488-95.

[14] Sekine Y, Yumioka T, Yamamoto T, Muromoto R, Imoto S, Sugiyma K, et al. Modulation of TLR4 signaling by a novel adaptor protein signal-transducing adaptor protein-2 in macrophages. J Immunol. 2006; 176: 380-9.

[15] Sekine Y, Tsuji S, Ikeda O, Sugiyma K, Oritani K, Shimoda K, et al. Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. J Immunol. 2007; 179: 2397-407.

[16] Sekine Y, Ikeda O, Tsuji S, Yamamoto C, Muromoto R, Nanbo A, et al. Signal-transducing adaptor protein-2 regulates stromal cell-derived factor-1α-induced chemotaxis in T cells. J Immunol. 2009; 183: 7966-74.

[17] Saitoh K, Kashiwakura JI, Kagohashi K, Sasaki Y, Kawahara S, Sekine Y, et al. STAP-2 is a novel positive regulator of TCR-proximal signals. J Immunol. 2022; 209: 57-68.

[18] Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004; 3: 301-17.

[19] Muller S, Zhao Y, Brown TL, Morgan AC, Kohler H. TransMabs: cell-penetrating antibodies, the next generation. Expert Opin Biol Ther. 2005; 5: 237-41.

[20] Marschall AL, Frenzel A, Schirrmann T, Schüngel M, Dübel S. Targeting antibodies to the cytoplasm. MAbs. 2011; 3: 3-16.

[21] Lee AC, Harris JL, Khanna KK, Hong JH. A comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 2019; 20: 2383.

[22] Sasaki Y, Saitoh K, Kagohashi K, Ose T, Kawahara S, Kitai Y, et al. STAP-2-derived peptide suppresses TCR-mediated signals to initiate immune responses. J Immunol. 2023; 211: 755-66.

[23] Langer R. Drug delivery and targeting. Nature. 1998; 392: 5-10.

[24] Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011; 164: 1079-106.

[25] Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int. 2008; 57: 115-20.

[26] Chyuan IT, Tsai HF, Wu CS, Sung CC, Hsu PN. TRAIL-mediated suppression of T cell receptor signaling inhibits T cell activation and inflammation in experimental autoimmune encephalomyelitis. Front Immunol. 2018; 9: 15.

[27] Engelmann S, Togni M, Thielitz A, Reichardt P, Kliche S, Reinhold D, et al. T cell-independent modulation of experimental autoimmune encephalomyelitis in ADAP-deficient mice. J Immunol. 2013; 191: 4950-9.

[28] McGinley AM, Edwards SC, Raverdeau M, Mills KHG. Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. J Autoimmun. 2018; 87: 97-108.

[29] El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010; 5: 189-97.

[30] Kalinke U, Prinz M. Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS. Immunol Cell Biol. 2012; 90: 505-9.

[31] Ikeda O, Sekine Y, Kakisaka M, Tsuji S, Muromoto R, Ohbayashi N, et al. STAP-2 regulates c-Fms/M-CSF receptor signaling in murine macrophage Raw 264.7 cells. Biochem Biophys Res Commun. 2007; 358: 931-7.

[32] Saitoh K, Tsuchiya T, Kashiwakura JI, Muromoto R, Kitai Y, Sekine Y, et al. STAP-2 interacts with Pyk2 and enhances Pyk2 activity in T-cells. Biochem Biophys Res Commun. 2017; 488: 81-7.

[33] Sekine Y, Yamamoto C, Ikeda O, Muromoto R, Nanbo A, Oritani K, et al. The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl. Biochem Biophys Res Commun. 2009; 384: 187-92.

[34] Sasikumar PG, Ramachandra RK, Adurthi S, Dhudashiya AA, Vadlamani S, Vemula K, et al. A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy. Mol Cancer Ther. 2019; 18: 1081-91.

[35] Fujita N, Oritani K, Ichii M, Yokota T, Saitoh N, Okuzaki D, et al. Signal-transducing adaptor protein-2 regulates macrophage migration into inflammatory sites during dextran sodium sulfate induced colitis. Eur J Immunol. 2014; 44: 1791-801.

[36] Ichii M, Oritani K, Toda J, Saito H, Shi H, Shibayama H, et al. Signal-transducing adaptor protein-2 delays recovery of B lineage lymphocytes during hematopoietic stress. Haematologica. 2021; 106: 424-36.

[37] Saito H, Ichii M, Toda J, Kitai Y, Muromoto R, Kashiwakura JI, et al. Graft- versus-host disease develops in mice transplanted with lymphocyte-depleted bone marrow cells from signal-transducing adaptor protein-2 transgenic mice . Biochem Biophys Res Commun. 2021; 537: 118-24.